NorthWest Biotherapeutics Inc (NWBO)

[Lykiri]

The company is question was not a competing company.

exwannabe,

That is not correct!

Northwest Biotherapeutics

FORM 10-K
ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the fiscal year ended December 31, 2017

Competition in the biotechnology and biopharmaceutical industry is intense, rapidly expanding and most of our competitors have substantially greater resources than we do.

The biotechnology and biopharmaceutical industries are characterized by rapidly advancing technologies, intense competition and a strong emphasis on proprietary products. A growing number of other companies, such as Juno, Kite Bellicum, Argos, Agenus, Asterias, Dandrit, Immunicum, Sotio, Tocagen and many others, are actively involved in the research and development of immune therapies or cell-based therapies for cancer.
https://www.sec.gov/Archives/edgar/data/1072379/000114420418020971/tv491101_10k.htm